文献速递神经免疫

降低多发性硬化治疗支出并提升健康系统层面的质量

Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
PubMed 文献 · Ann Neurol · 2022-03-30

本研究评估了旨在降低不断攀升的疾病修饰治疗(DMT)支出并通过增加优选处方集和高疗效DMT(HET)使用来改善多发性硬化(MS)结局的多组分健康系统干预。

要点

  • MSTOP实施后优选处方集DMT依从性从25.4%升至72.2%,对照区域从22.1%升至43.8%。
  • HET使用增至62.5%治疗人年,DMT治疗患者调整后年复发率下降69%。

核心结论

  • 一种由专家主导的新型健康系统干预在价格上涨的情况下降低了MS的DMT支出,同时降低了MS复发率。
  • 作者认为,聚焦健康系统朝着有意义、可衡量目标取得的进展,可作为改善其他环境下MS照护质量与可负担性的模型。

研究设计与样本

  • 研究为趋势研究,比较KPSC在MSTOP实施前(2009-2011年)与实施期间(2012-2018年)的治疗利用与支出结局,并与规模相近的Kaiser Permanente地区进行比较。
  • 年复发率(ARR)取自KPSC的电子健康记录。

主要发现

  • KPSC优选处方集DMT依从性从2011年25.4%升至2017年72.2%,对照区域从22.1%升至43.8%。
  • KPSC 2018年年度DMT支出低于2011年,尽管接受DMT治疗的成员增加了11.3%。
  • HET使用增至62.5%的治疗人年,对照区域为32.4%;KPSC DMT治疗患者调整后ARR下降69%(95%CI 64.1-73.2%;p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to evaluate a multicomponent health system intervention designed to reduce escalating disease-modifying treatment (DMT) expenditures and improve multiple sclerosis (MS) outcomes by increasing use of preferred formulary and highly effective DMTs (HETs). METHODS: We conducted a trend study of treatment utilization and expenditure outcomes prior to (2009-2011) and during (2012-2018) MS Treatment Optimization Program (MSTOP) implementation in Kaiser Permanente Southern California (KPSC) compared to a Kaiser Permanente region of similar size. Annual relapse rates (ARRs) were obtained from KPSC's electronic health records. RESULTS: Adherence to preferred formulary DMTs increased from 25.4% in 2011 to 72.2% in 2017 following MSTOP implementation in KPSC and 22.1% to 43.8%, respectively, in the comparator. KPSC's annual DMT expenditures in 2018 were less than in 2011 despite an 11.3% increase in DMT-treated members. The decline in average per patient per year of treatment expenditures from a peak of $43.1 K in 2014 to $26.3 K in 2018 in KPSC was greater than the comparator, which peaked at $52.1 K and declined to $40.0 K in 2018. Over the 7 years following initiation of MSTOP, cumulative MS DMT expenditures were $161.6 million less than the comparator. HET use increased to 62.5% of per patient treatment-years versus 32.4% in the comparator. This corresponded to a 69% decline in adjusted ARR (95% confidence interval = 64.1-73.2%; p < 0.0001) among DMT-treated patients in KPSC. INTERPRETATION: A novel, expert-led health system intervention reduced MS DMT expenditures despite rising prices while simultaneously reducing MS relapse rates. Our focus on health system progress toward meaningful, measurable targets could serve as a model to improve quality and affordability of MS care in other settings. ANN NEUROL 2022;92:164-172.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Langer-Gould A, Cheng SC, Li BH, et al. Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level. Ann Neurol. 2022. PMID: 35285095. doi:10.1002/ana.26352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。